Nucleus Capital
Nucleus Capital is a Berlin-based first-check deep-tech venture firm founded in 2020 by Isabella Fandrych and Maximilian Schwarz, investing at pre-seed and seed stage in programmable biology (synbio and techbio), food technology and neo-industrials across Europe and the US. Backed by KfW Capital, the European Investment Fund and Rentenbank, it runs a concentrated, thesis-driven portfolio of scientifically-led founders tackling human and planetary health. The firm operates its legal entity as Nucleus Capital Fund Management GmbH and recorded its first exit when portfolio company Officinae Bio was acquired by Maravai LifeSciences in 2025.
Nucleus Capital is a Berlin venture capital firm with €47M AUM, 22 active companies and 1 exit.
- ·Top sector focus: Biotech (39% of portfolio).
- ·Fund cadence: ~3Y between vintages · last raise 2024.
Sector breakdown
23 companiesGeography breakdown
7 geographiesKey facts
Recent exits
Nucleus Capital sold Officinae Bio to Maravai LifeSciences in 2025 after 4 years.
Partners
Coverage notes
2 funds tracked, 23 portfolio companies (22 active · 1 realized). Verified weekly from public filings and deal announcements.
Investment team
Senior partners. Hand-checked from public filings and the firm's own site.
Funds & portfolio
Every fund Nucleus Capital has raised, with its portfolio companies. Hand-checked from public filings.
Nucleus Capital IIVC2024€40M8 assetsVC2024 · 2yr€40M8–
Unrealized
8 held| Company | Entry |
|---|---|
| Apoha Deep Tech · UK | 2024 |
| AtmoCooling ClimateTech · US | 2025 |
| Bindbridge Biotech · UK | 2026 |
| Izote Biosciences Biotech · US | 2024 |
| Ruby Bio Biotech · US | 2025 |
| Spark E-Fuels ClimateTech · Germany | 2025 |
| Telura ClimateTech · Germany | 2025 |
| Triple Bio Biotech · Netherlands | 2026 |
Nucleus Capital IVC2021€7M14 assets1 exitsVC2021 · 5yr€7M141
Unrealized
14 held| Company | Entry |
|---|---|
| atmio ClimateTech · Germany | 2023 |
| Biographica Biotech · UK | 2023 |
| Biomia Biotech · Denmark | 2023 |
| Brineworks ClimateTech · Netherlands | 2023 |
| Concert Bio Biotech · UK | 2022 |
| Endolith Industrials · US | 2023 |
| Farmless FoodTech · Netherlands | 2023 |
| Grounded Foods FoodTech · US | 2021 |
| Juicy Marbles FoodTech · Slovenia | 2021 |
| Planet A Foods FoodTech · Germany | 2021 |
| Rhizocore Technologies ClimateTech · UK | 2022 |
| Root Global ClimateTech · Germany | 2022 |
| Vosbor Business Services · Netherlands | 2022 |
| Yuri Biotech · Germany | 2021 |
Realized
1 exit| Company | Entry | Exit | Type | Buyer | MOIC |
|---|---|---|---|---|---|
| Officinae Bio Biotech · Italy | 2021 | 2025 | Trade Sale | Maravai LifeSciences | – |
Frequently asked questions
- What investment strategy does Nucleus Capital focus on?
- Nucleus Capital focuses on VC strategies in the private equity space.
- How many portfolio companies does Nucleus Capital have?
- Nucleus Capital has 22 active portfolio companies and 1 completed exit and 2 funds tracked on GP Intel.
- Where is Nucleus Capital headquartered?
- Nucleus Capital is headquartered in Berlin, Germany.
- What is Nucleus Capital's assets under management?
- Nucleus Capital manages approximately €47M in assets under management.
- When was Nucleus Capital founded?
- Nucleus Capital was founded in 2020.
- What sectors does Nucleus Capital invest in?
- Nucleus Capital invests across Healthcare, Consumer, Industrials, Energy.
- What are Nucleus Capital's recent exits?
- Recent realized exits by Nucleus Capital include: Officinae Bio (2025) to Maravai LifeSciences.
Similar firms
Other private equity firms tracked on GP Intel.
Germany·€46M
Germany·€46M
Germany·€45M
Germany·€50M
Germany·€50M
Germany·€55M
Germany·€39M
Germany·€38M
Germany·€60M
Germany·€30M
Germany·€28M
Germany·€20M